Literature DB >> 8836335

Economic analysis of two structured treatment and teaching programs on asthma.

M Neri1, G B Migliori, A Spanevello, D Berra, E Nicolin, C V Landoni, L Ballardini, M Sommaruga, P Zanon.   

Abstract

The aims of the present study were as follows: 1) to evaluate the medical outcomes of two treatment and educational asthma programs 2) to determine by cost-analysis both cost and economic outcome of the programs 3) to perform a cost-benefit analysis (determining the net cost-benefit) and a cost-effectiveness analysis (determining the cost per unit of effect and the incremental cost-effectiveness ratio) from the perspective of health program policy makers (HPP; indirect costs, i.e., loss of productivity, excluded) and of society as a whole (SaW, all costs included). Patients were randomly assigned to a complete (CP; n = 32) or reduced (RP; n = 33) program: the RP group received a reduced education (self-reading of an educational booklet on asthma), while the CP group attended an "asthma school", consisting of six lessons based on the same booklet and including educational videotapes. Both programs included peak-flow monitoring and treatment according to international guidelines, and follow-up. The outcome variables (asthma attacks, urgent medical examinations, admission days, working days lost) did not differ significantly between CP and RP. Morbidity savings were $1894.70 (CP) and $1697.80 (RP) according to SaW, and $1349.50 and $1301.80, respectively, according to HPP. The net cost-benefit was $1181.50 for CP and $1028.00 for RP, and the cost-benefit ratio per dollar spent was 1:2.6 for CP and 1:2.5 for RP, according to SaW. One day of admission prevented had a cost of $110.20 (CP) and $94.10 (RP). CP gave slightly better results and was slightly more cost-effective than RP in improving patients' welfare. It cannot be excluded that the retrospective analysis used to determine baseline costs might have inflated differences for both groups. Sensitivity analysis was slightly in favor of RP when the outcome variables were tested at their upper and lower 95% CI.

Entities:  

Mesh:

Year:  1996        PMID: 8836335

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  6 in total

Review 1.  The limited incorporation of economic analyses in clinical practice guidelines.

Authors:  Joel F Wallace; Scott R Weingarten; Chiun-Fang Chiou; James M Henning; Andriana A Hohlbauch; Margaret S Richards; Nicole S Herzog; Lior S Lewensztain; Joshua J Ofman
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

Review 2.  Chronic bronchial asthma from challenge to treatment: epidemiology and social impact.

Authors:  M Neri; A Spanevello
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 3.  Objectives, methods and content of patient education programmes for adults with asthma: systematic review of studies published between 1979 and 1998.

Authors:  P Sudre; S Jacquemet; C Uldry; T V Perneger
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

4.  [An increase in allergic diseases in childhood--current hypotheses and possible prevention].

Authors:  Herbert Kurz; Jose Riedler
Journal:  Wien Med Wochenschr       Date:  2003

5.  Economic evaluation of enhanced asthma management: a systematic review.

Authors:  Yee V Yong; Asrul A Shafie
Journal:  Pharm Pract (Granada)       Date:  2014-03-15

6.  Economic evidence for nonpharmacological asthma management interventions: A systematic review.

Authors:  C-J Crossman-Barnes; A Peel; R Fong-Soe-Khioe; T Sach; A Wilson; G Barton
Journal:  Allergy       Date:  2017-11-13       Impact factor: 13.146

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.